BTG discontinues paclitaxel gel after Phase IIb failure
This article was originally published in Scrip
Executive Summary
BTG's OncoGel (paclitaxel gel) has failed to demonstrate any effect on tumour response in a Phase IIb trial and is being dropped from development.